Study ID	Study follow‐up (months)	ChAdOx1 (n)	Placebo (n)	Critical outcomes
				Confirmed SARS‐CoV‐2 infection after complete vaccination	Confirmed symptomatic COVID‐19 after complete vaccination	Severe or critical COVID‐19	All‐cause mortality	Systemic reactogenicity events	Any AE	SAE
Asano 2022 (NCT04568031)	1.9	192	64	*	*	*	✓	✓	✓	✓
Falsey 2021 (NCT04516746)	6.27	21,635	10,816	✓	✓	✓	✓	*	✓	✓
Clemens 2021a (ISRCTN89951424)	8.27	5207	5209	*	✓	✓	✓	X	*	X
Emary 2021 (NCT04400838)	4.93	5600	5211	*	✓	*	*	*	*	*
Madhi 2021b  (NCT04444674; PACTR202006922165132)	2	52	52	*	*	*	✓	*	*	✓
Madhi 2021a  (NCT04444674; PACTR202006922165132)	6.73	1013	1013	*	✓	*	*	*	*	*
Kulkarni 2021 (CTRI/2020/08/027170)	6	900	300	*	*	*	✓	X	✓	✓
Voysey 2021a (NCT04324606; ISRCTN89951424; NCT04400838; NCT04444674)	3.94	12,408	12,014	✓	✓	✓	✓	*	✓	✓
Voysey 2021ab (ISRCTN89951424; NCT04324606; NCT04400838; NCT04444674)	3.94	12,048	12,014	✓	✓	✓	✓	*	✓	✓